Shares of Kodiak Sciences Inc. KOD plummeted today as investors reacted to a disappointing financial report by the company. Kodiak Sciences posted a wider-than-expected fourth-quarter loss,
sending its shares tumbling by nearly 20%.
The company’s quarterly loss of $1.13 per share missed market expectations, which anticipated a loss of 77 cents per share. Kodiak Sciences shares now stand at $5.97, reflecting the sharp decline in
investor confidence.
While Kodiak Sciences struggled, a different tune played out for several other stocks in today’s mid-day session, with notable gainers capturing investors’ attention.
Highlights in Gainers’ Camp
- Avalo Therapeutics, Inc. AVTX shares skyrocketed by 430% to $25.35 following the acquisition of a Phase 2-ready anti-IL-1β mAb, AVTX-009.
- Xilio Therapeutics, Inc. XLO surged 146% to $1.58 with the announcement of an exclusive license agreement with Gilead Sciences.
- Biodexa Pharmaceuticals Plc BDRX witnessed an 80% surge to $1.5395 on positive results for its MTX110 against aggressive brain cancers.
Down in the Dumps: Losers’ Tale
- Primech Holdings Ltd. PMEC saw its shares slump by 46.7% to $2.07 following the release of financial updates and corporate highlights.